Please login to create your UC TechAlerts.
Request a new password for
Required
Combination Therapy For Ad From Data
Brief description not available
Inhaled Hypoxia And Small Molecule Forms Of Hypoxia As Novel Anticancer Agents
Ex Vivo Enrichment And Expansion Of Chimeric Antigen Receptor T Cells Using Antigen-Presenting Biomaterials
Computational Drug Repurposing For Endometriosis
Cross-Tissue Transcriptomic Analysis Leveraging Machine Learning Approaches Identifies New Biomarkers For Rheumatoid Arthritis
Stem Cell Production In Space
Polymorphonuclear (Pmn) Cell Inhibition To Facilitate Cell Transplantation
Composite Epitope Cd19/Cd81 Nanobodies For Modulation Of B Cell Activation
Lacripep Promotes Neuroregeneration And Maintains Epithelial Progenitor Cell Identity In The Diseased Cornea
Haq Sting As A Treatment For Copa Syndrome
The Isolated Heparin-binding Domain (HBD) of VEGF165 and the Isolated D1 Domain of VEGFR2 (KDR)
Researchers at the University of California, Davis have developed recombinant fusion protein compositions that inhibit pathological angiogenesis by targeting VEGF165-KDR interactions to treat cancers and related diseases.
Methods of Improving Cancer Immunotherapy
Researchers at the University of California, Davis have developed methods that combine immunotherapeutic agents with dual inhibitors to enhance cancer treatment efficacy and prolong patient survival.
Programmable Peptide Nucleic Acid-Based Nanoplatform for Customizable Drug Delivery
Researchers at the University of California, Davis have developed a peptide nucleic acid-based system enabling precise and customizable delivery of antigens, adjuvants, and targeting molecules for improved cancer immunotherapy.
1-(Benzo[1,2-b:4,5-b']Difuran-4-yl)alkyl-2-amines and 1-(2,3,6,7-Tetrahydrobenzo[1,2-b:4,5-b']Difuran-4-yl)butan-2-amines as Serotonin Receptor Modulators for Neurodegenerative Disorders
Researchers at the University of California, Davis have developed novel serotonin receptor modulators designed as mixed 5-HT2A/2C partial agonists that demonstrate promising disease-modifying potential for Parkinson’s Disease with improved safety and efficacy.
Genomic Destructive CRISPR Guide RNAs
Reusable, Sterilizable Surgical Instruments for Deployment of Neuropixels Probes in the Operating Room
Researchers at the University of California, Davis have developed a system of reusable, sterilizable 3D-printed surgical tools that enables safe, precise intraoperative deployment of Neuropixels probes within standard neurosurgical workflows.
Using Class I Lasso Peptides to Inhibit the Bacterial Type III Secretion System
Antibiotic resistance is a major issue in infectious disease treatment and prevention. In bacteria, the type III secretion system (T3SS) secretes effector proteins in the host cell, allowing the pathogen to infect. The T3SS is largely found on pathogens and not beneficial bacteria, so targeting the T3SS might have an advantage over using classic antibiotics, which disturb the beneficial human microbiome.
Arg Accelerates Proximity-Enabled Sufex Reaction Rate In Proteins
Improvement Of Glycemic Control Through Beta-Cell Administration Of Mir192
AAV-Based Gene Therapy for Glioblastoma Treatment Using Interferon Cytokines
Enhancing Cancer Immunotherapy with Modified Adaptor Protein and CAR-NK Cell Technology
Next-Generation Monoclonal Antibody Therapy Targeting High-Risk Tumors
Affinity-Matured Anti-Cd72 Nanobodies For Next-Generation CAR-T Immunotherapies
Vaccines Using Macrophage Suppression
Researchers at the University of California, Davis have developed a technology that introduces vaccines that express macrophage-suppressing molecules to significantly enhance inflammatory T-cell functions for improved immune responses.
Lung-Targeted Cell-Based Therapies for Inflammatory Disease and Cancer